Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study

Table 1

Baseline characteristics of the study population.

	Total ( = 325)
Indication to start triptorelin treatment at baseline
Neoadjuvant before radical prostatectomy	5 (1.5%)
Neoadjuvant before radiotherapy or brachytherapy	62 (19.1%)
Adjuvant after radical prostatectomy	12 (3.7%)
Adjuvant after radiotherapy or brachytherapy	4 (1.2%)
Rising PSA after radical prostatectomy	29 (8.9%)
Rising PSA after radiotherapy or brachytherapy	23 (7.1%)
Locally advanced, first line therapy	135 (41.5%)
Locally advanced, after antiandrogen therapy	7 (2.2%)
Metastatic, first line therapy	43 (13.2%)
Other	17 (5.2%)
Missing data	0
Age at first prostate cancer diagnosis (years)
Mean (SD)	72.86 (8.26)
TNM staging: T
T1	10 (3.1%)
T1	1 (0.3%)
T1a	1 (0.3%)
T1b	3 (0.9%)
T1c	5 (1.6%)
T2	47 (14.7%)
T2	26 (8.1%)
T2a	7 (2.2%)
T2b	9 (2.8%)
T2c	5 (1.6%)
T3	241 (75.1%)
T3	182 (56.7%)
T3a	43 (13.4%)
T3b	16 (5.0%)
T4	22 (6.9%)
T	1 (0.3%)
Missing data	4
TNM staging: N
N0	178 (57.1%)
N1	43 (13.8%)
N	91 (29.2%)
Missing data	13
TNM staging: M
M0	199 (63.4%)
M1	35 (11.1%)
M1	28 (8.9%)
M1a	1 (0.3%)
M1b	6 (1.9%)
M	80 (25.5%)
Missing data	11
Gleason score
≤6	106 (35.5%)
7	99 (33.1%)
≥8	94 (31.4%)
Missing data	26